Abstract: Lung cancer is the most common cancer and the leading cause of cancer death worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018. Although small cell lung cancer (SCLC) is the most aggressive type of lung cancer, it shows high response rates to chemotherapy in early lines of therapy. Unfortunately, it is associated with rapid recurrence and relatively poor prognosis. Over the last few years, considerable progress has been made in cancer immunotherapy. One of the most promising ways to activate therapeutic antitumor immunity is via blockade of immune checkpoints, such as cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1). Immune checkpoint inhibitors show promise as SCLC therapeutics. The overall expectation for immuno-oncology is high, and the outcomes of trials will hopefully reveal a variety of treatment options for SCLC patients. In this review, we discuss the discovery of new immune inhibitory and stimulatory pathways and rational combination strategies to explain the role of immunotherapy in SCLC and its future opportunities and challenges.
Introduction
Lung cancer is the most common cancer and the leading cause of cancer death worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018. 1 Approximately 13% of lung cancer patients have small cell lung cancer (SCLC). 2 Although this aggressive tumor shows high response rates to chemotherapy in early lines of therapy, it is associated with rapid recurrence and relatively poor prognosis and is often diagnosed at late stages with systemic metastasis. 3, 4 Thus, the 5-year survival of SCLC patients is very low and varies according to stage, with 5-year relative survival rates of 31% for limited-stage SCLC (LS-SCLC) but just 2% for extensive-stage SCLC (ES-SCLC). 5 Because SCLC is generally highly sensitive to chemotherapy and radiation therapy, combined chemotherapy and radiotherapy has become the accepted standard treatment for all stages of SCLC. The standard chemotherapy regimen of cisplatin or carboplatin plus etoposide used as the first-line treatment of LS-SCLC and ES-SCLC diseases has not changed over the past four decades. Radiotherapy is administered to those patients with LS-SCLC whose cancer is confined to the chest in a single tolerable radiation field. [6] [7] [8] Recently, the randomized phase III CONVERT trial 9 was designed to show the superiority of once-daily concurrent radiotherapy. However, because it was not powered to show equivalence, the standard of care arguably remains twice-daily therapy, although its use is less frequent. These results indicate conventional or hyperfractionated radiotherapy as the potential standard of care in LS-SCLC. Although up to 80% of patients respond to first-line chemotherapy and radiation therapy, most rapidly relapse and show resistance to further therapies. Recently, many improvements have been made to the fundamentals of SCLC treatment. The results of the CheckMate-032 study contributed to the first Food and Drug Administration (FDA)-accelerated approval for nivolumab (OPDIVO ® , anti-programmed cell death protein-1 [PD1]) for the third-line treatment of metastatic SCLC in August 2018.
However, the open-label Checkmate-331 study failed to meet the primary endpoint of overall survival (OS) compared with standard of care. 10 Recently, the results of the IMpower study contributed to FDA-accelerated approval of the combination of atezolizumab (TECENTRIQ ® ) with carboplatin and etoposide in the frontline treatment of ES-SCLC in March 2019. 11 The study demonstrated an overall survival benefit when the programmed cell death ligand-1 (PD-L1) inhibitor atezolizumab was added to platinum/etoposide chemotherapy for the initial treatment of ES-SCLC (median OS 12 In Figure 1 , we summarize the standard of care therapies and new therapies that have been approved by the FDA. Additionally, the FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for pembrolizumab (KEYTRUDA ® ) as a treatment for patients with advanced SCLC whose disease has progressed after two or more prior lines of therapy. 13 The application is based on findings from cohorts of the phase II KEYNOTE-158 and phase Ib KEYNOTE-028 studies, in which pembrolizumab elicited 19% and 33% overall response rates (ORRs) in patients with advanced and ES-SCLC, respectively. 14, 15 The immune system can recognize physiological and pathological changes at the cellular level. After tumorigenesis, tumor-associated antigens can be presented by antigen-presenting cells (APCs) to major histocompatibility complex (MHC) I and then recognized by T cell receptor on CD8 cytotoxic T cells. T cell activation is induced by a secondary co-stimulatory signal, namely, the binding of B7 protein on APCs to CD28 on cytotoxic T cells. Afterward, the activated T cell induces the death of the physiologically and pathologically altered cell. Conversely, the activated T cells are negatively regulated by increased expressed of cytotoxic T lymphocyteassociated protein 4 (CTLA-4), which has a higher affinity for B7 protein of APCs than the CD28 molecule of cytotoxic T cells. 16 CTLA-4 is normally expressed in regulatory T cells (Tregs) and acts as a restraint molecule of the activated immune system, suppressing auto-reactivity. Similar to the CTLA-4 molecule, PD-1 is an immune checkpoint inhibitor in activated T cells, peripheral B cells, and myeloid cells. In contrast, the binding of PD-1 to PD-L1 on tissues or hematopoietic cells occurs in the late phase and thereby mainly suppresses activated T cells in peripheral immune effector sites rather than in central lymph systems. 17, 18 Overexpression of tumor-specific antigens on tumor cells can facilitate their recognition by the host immune system, especially by T cells. 19 CTLA-4 and PD-1 are recognized as inhibitors of immune effector cells and they therefore contribute to the rapid development of cancer cells due to inactivation of the immune system during tumorigenesis. Because SCLC has the highest rate of tumor mutational burden (TMB), the tumor should be sensitive to immunebased therapeutic approaches. 20, 21 TMB is used as a predictor of immune checkpoint inhibitor efficacy for many cancer types. 22 In Helmann et al, 23 the objective response rate was 21.3% in the high TMB group (248 mutations on whole-exome sequencing) but just 4.8% in the lower TMB group (0 to 142 mutations). PD-L1 expression has been applied as a biomarker to predict the efficacy of PD-1/PD-L1 inhibitors in relation to the dynamic and heterogeneous expression of PD-L1 in the tumor microenvironment. 24 Immune checkpoint molecules are frequently overexpressed in SCLC-associated tumor-infiltrating lymphocytes. The CTLA-4 pathway and CTLA-4 checkpoint inhibitors CTLA-4 was the first immune checkpoint receptor to be targeted by a therapeutic agent. 26 Monoclonal antibodies against CTLA-4 (ipilimumab and tremelimumab) are designed to prevent the interaction between CTLA-4 and its ligands (CD80/CD86). In this manner, they blockade the inhibitory signal provided by CTLA-4 and enhance the activation and proliferation of tumor-specific T cells, facilitating an effective immune response against tumor cells. In 2011, ipilimumab became the first immune checkpoint inhibitor to be approved by the FDA. [27] [28] [29] As shown in Table 1 , ipilimumab has been investigated in combination with chemotherapy in patients with SCLC. [30] [31] [32] Ipilimumab has achieved promising results in SCLC treatment. 33 In a three-arm phase II trial (NCT00527735), patients received either six cycles of carboplatin and paclitaxel with or without ipilimumab or with ipilimumab in a phased schedule. 31 The immune-related progression-free survival (irPFS) was significantly prolonged for the phased ipilimumab arm (6.4 vs. 5.3 months, HR 0.64, P=0.03) but was not prolonged for the concurrent arm compared with the control (5.7 vs. 5.3 months, HR 0.75, P=0.11). There was also a nonsignificant trend for improved OS in the phased ipilimumab arm (mOS 12.5 months, 95% CI 7.9-14.9), compared with mOSs of 9.1 months (95% CI 6.7-13.0) for the concurrent arm and 10.5 months (95% CI 8.6-11.7) for the control arm. The HR values relative to control were 0.76 (95% CI 0.48-1.19, P=0.13) for phased ipilimumab and 0.89 (95% CI 0.57-1.39, P=0.41) for concurrent ipilimumab. 31 There was also increased toxicity, with grade III and IV toxicities more common in the ipilimumab arms (30% control vs. 43% concurrent vs. 50% phased). The study did not identify any potential biomarkers that could predict the response to ipilimumab treatment in patients with SCLC (Table 1) .
In an open-label phase II study 30 .032). The mPFS (mPFS) was 6.9 months (95% CI 5.5-7.9), the median irPFS was 7.3 months (95% CI 5.5-8.8), and the mOS was 17 months (95% CI 7.9-24.3). Increased toxicity was detected, with grade III or higher toxicity developing in 90%; 69% of these toxicities were thought to be related to ipilimumab. Moreover, in a double-blind phase III study of ipilimumab plus etoposide and a platinum agent, OS was not increased compared with chemotherapy alone (mOS of 11.0 vs. 10.9 months, HR 0.94, 95% CI 0.81-1.09, P=0.3775). 32 There was also no significant improvement in the mPFS (4.6 vs.4.4 months; HR 0.85, 95% CI 0.75-0.97). Rates of treatment-related adverse events were 48% for grade III to IV events in the ipilimumab arm and 44% in the placebo arm (Table 1) .
PD-1 and PD-L1 pathways and PD-1 and PD-L1 checkpoint inhibitors
The PD-1 receptor is another important checkpoint receptor being studied in oncology. 34 In contrast to CTLA- In the CheckMate-032 study, 38 the mOS was 4.4 months (95% CI 3.0-9.3) in the nivolumab monotherapy arm but 6.0 months (95% CI 3.6-11.0) in the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3/I1) arm and 43 investigating the therapeutic efficacy of single atezolizumab for relapsed SCLC revealed that atezolizumab did not have a significantly better therapeutic efficacy and safety profile. PFS was determined to be 1.4 months in the atezolizumab group (95% CI 1.2-1.5) but 4.2 months in the chemotherapy group (95% CI 1.5-5.9). In this field of study, several clinical trials are still being performed to evaluate the efficacy and safety of atezolizumab for SCLC. In addition, other PD-L1 immune checkpoint inhibitorsdurvalumab and avelumab-are also being investigated in clinical trials. 44 
Combination therapy
A number of ongoing trials are focused on combination therapies, such as a phase I/II trial investigating ROVA-T (an anti-DLL3 antibody drug conjugate) with nivolumab and ipilimumab (NCT03026166) and a phase I/II trial investigating olaparib (PARP inhibitor) with durvalumab (anti-PD-L1 antibody) and the anti-VEGF antibody bevacizumab (NCT02734004).
A randomized, open-label, phase II study (STIMULI) comparing ipilimumab following chemoradiotherapy alone in LS-SCLC is currently recruiting patients (NCT02046733) 44 with primary endpoints of OS and PFS. In the induction phase, nivolumab is to be administered at a dose of 1 mg/kg i.v., followed by ipilimumab 3 mg/kg i.v. once every 3 weeks for four cycles. Nivolumab will be continued as maintenance therapy at a dose of 240 mg i.v. once every 2 weeks for a maximum of 12 months; the results are expected in 2022. Phase III data from the CheckMate-451 trial showed that OPDIVO ® (nivolumab) combined with YERVOY ® (ipilimumab) missed the primary endpoint of OS. 45 Preliminary results from the BALTIC study, 46 which evaluated the combination of durvalumab and tremelimumab in 25 patients with platinum-refractory/platinum-resistant ES-SCLC, showed an objective response rate of 9.5%, mPFS of 1.9 months, and mOS of 6.0 months, suggesting improved activity over single-agent anti-PD-L1 therapy (Table 2) . A phase I/II study 44 comparing nivolumab+ipilimumab ±plinabulin in recurrent SCLC is currently recruiting patients (NCT03575793). Primary endpoints include the maximum tolerated dose and PFS. In the phase I trial, nivolumab is to be intravenously administered at a dose of 1 mg/kg i. . After four treatment cycles, ipilimumab will be stopped and patients will be administered nivolumab 240 mg and plinabulin every 2 weeks; the results are due in 2022. A number of ongoing trials are focusing on durvalumab and tremelimumab combination therapies, such as the CASPIAN and CLOVER trials. A phase III study (CASPIAN) comparing durvalumab with or without tremelimumab after chemotherapy alone in ES-SCLC patients is currently active and not recruiting patients (NCT0304872). 44 Its results are expected in 2020. The primary endpoints of the clinical trial include OS. The trial is designed as follows. In Arm A, durvalumab and tremelimumab are administered every 3 weeks for 12 weeks and carboplatin/cisplatin and etoposide are administered up to four cycles every 3 weeks. In Arm B, durvalumab is administered every 3 weeks for 12 weeks and carboplatin/cisplatin and etoposide are administered up to four cycles every 3 weeks. In Arm C, carboplatin/cisplatin and etoposide are administered up to six cycles every 3 weeks ( Table 2 ).
Next generation of immune checkpoint targets
Immune checkpoint molecules are important regulators for maintaining immune homeostasis and preventing autoimmunity. These pathways consist of both stimulatory and inhibitory pathways, which are important for maintaining self-tolerance and regulating the type, magnitude, and duration of the immune response, 34, 47 as shown in Figure 1 . 44 The primary endpoint is the number of participants with dose-limiting toxicities in the first 8 weeks of treatment and those with an objective response. Currently, no data are unavailable on SCLC (Table 3) .
LAG3

4-1BB
4-1BB, an activation-induced co-stimulatory receptor, is an important regulator of immune responses that is expressed by T cells, NK cells, and APCs. Once expressed, it binds to its ligand (4-1BBL) and triggers the proliferation and activation of immune cells, particularly T and NK cells. 57, 58 Utomilumab (PF-05082566), a fully human monoclonal antibody that stimulates 4-1BB, is currently being studied in patients with SCLC and in combination with avelumab and PF-04518600 in a phase II clinical trial (JAVELIN Medley). 44 The primary endpoint is the number of participants with dose-limiting toxicities in the first 8 weeks of treatment and those with an objective response. Utomilumab is administered to those who have progressed after at least one line of platinum-containing therapy, and one of three dose levels is to be used to optimize the combination with avelumab until disease progression. No preliminary results are available yet (Table 3) .
Non-t cell-associated inhibitory molecules TGF-β
Transforming growth factor (TGF)-β is a cytokine that controls multiple cellular processes such as growth suppression of epithelial cells, alveolar epithelial cell differentiation, fibroblast activation, and extracellular matrix organization.
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The TGF-β pathway promotes cancer progression by concomitantly boosting tumor metastasis while inhibiting the host immune response. Although this pathway is able to control early-stage tumors by promoting cell cycle arrest and apoptosis, in advanced stages, it allows for tumor evasion by suppressing cytotoxic T cells and promotes cancer cell proliferation, invasion, and metastasis, a functional switch known as the TGF-β paradox. 60, 61 M7824 is a monoclonal antibody against PD-L1 linked to the extracellular domain of human TGF-β receptor 2 protein. Upon administration, the PD-L1 monoclonal antibody part of M7824 binds to PD-L1 while the TGF-β part binds to and neutralizes TGF-β receptor 2 protein, which prevents TGF-β-and PD-L1-mediated signaling and promotes CD8+ T cell and NK cell activation, ultimately inhibiting tumor growth. 61, 62 M7824 is being evaluated in a phase I/II clinical trial (NCT03554473) in patients with relapsed SCLC. 43 The primary endpoints include efficacy (after 6 weeks for Arm B and 8 weeks for Arm C), PFS, duration of response, and OS. M7824 is administered at 1800 mg i. (Table 3) .
IDO
Indoleamine 2.3-dioxygenase (IDO) is an intracellular enzyme that converts tryptophan to kynurenines. Kynurenines promote the differentiation and activity of Treg cells and decrease the amount and activity of CD8 T cells, which prompts an immunosuppressive situation that is compounded by the elevated amounts of PD-1/PD-L1 present in this milieu. 63, 64 Epacadostat is an oral agent that blocks the IDO pathway and is being investigated in a phase I/II clinical trial of advanced and metastatic malignancies including SCLC (NCT03277352). 44 The primary endpoints include treatment-emergent adverse events, objective response rate, and the complete response rate. Treatmentemergent adverse events are screened through 60 days after the end of treatment up to 18 months for phase I. The objective response rate and complete response rate are to be assessed every 9 weeks for 12 months, then every 12 weeks up to 18 months for the phase II trial. Moreover, a nonrandomized, open-label, phase I/II clinical trial of advanced solid tumors including SCLC (NCT03361228) 44 is currently active and not recruiting patients. The primary endpoints include treatment-emergent adverse events and objective response rate, assessed up to approximately 12 months. No preliminary results are available yet (Table 3) .
Conclusion
Immune checkpoint inhibitors are showing promise as therapeutic agents for SCLC and are being intensively studied. Thus, numerous trials at all stages and lines of treatment of SCLC are exploring the value of these agents both alone and in combination with chemotherapy or targeted agents. Overall, the expectations for immuno-oncology are high and the outcomes of these trials will hopefully reveal a variety of treatment options for SCLC patients. The discovery of new immune inhibitory and stimulatory pathways and rational combination strategies as discussed in this article is essential and will help to improve SCLC immunotherapy.
